Development

Burgeoning CGT modalities bring promise and challenges.

Scale-up strategies for cell culture will require a deep understanding of overall bioprocess workflows.

Advanced analytical tools generate more data in today’s labs than ever before.

mRNA may be a modality whose chief advances are yet to come.

Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.

Janssen has received a positive opinion from the EMA for two novel bispecific antibodies, TALVEY (talquetamab) and TECVAYLI (teclistamab), which the company is developing to treat blood cancer.

Newly launched Crossbow Therapeutics will work to advance a novel class of antibody therapies for treating cancers.

Webinar Date/Time: Tue, Aug 15, 2023 11:00 AM EDT

Exploring new fields can bring novel antibody candidates to the pipeline.

Camena Bioscience has completed $10 million in Series A financing on the back of growing demand for DNA synthesis.

Thermo Fisher Scientific’s new tumoroid culture medium kit is designed to help cancer researchers better model the disease.

Eurofins Genomics Blue Heron’s novel mRNA synthesis service is designed for customizable applications.

Chime Biologics, Leads Biolabs, and BeiGene have formed a three-way collaboration to advance the development and global manufacturing of Leads Biolabs’ lead mAb candidate, LBL-007.

Despite many development challenges, stable producer cell lines show real promise.

If we view a change opposite of one’s interest as antithetical to innovation, we risk losing sight of our ultimate goal.

Webinar Date/Time: Wed, Jul 19, 2023 11:00 AM EDT

Image analysis algorithms coupled with microscopy techniques can be used to characterize aggregates of therapeutic proteins.

Sandbox AQ’s molecular simulation division is collaborating with companies like AstraZeneca and Sanofi to develop novel treatments for various disorders.

Webinar Date/Time: Tue, Aug 29, 2023 11:00 AM EDT

Webinar Date/Time: Wednesday, August 30, 2023 at 11am EDT

The new excipients manufacturing facility is expected to be completed in 2025.

There are various challenges associated with the development of CAR-T therapies for solid tumor cancers.

When one is using continuous hot-melt extrusion to enhance solubility, process control is essential.

invoX Pharma has made a second tranche of investment in pHion Therapeutics to support further development of next-generation mRNA vaccines.

New fields are being explored to bring novel antibody candidates to the pipeline.

Compliance with GMP standards remains an integral focus in bulk mAb manufacturing.

Scaling cell therapy production workflows requires the establishment of closed, automated steps.

A partnership between Rentschler Biopharma and Ikarovec will support the accelerated development of novel gene therapies for the treatment of eye diseases.

The start of production of US engineering batches of NXC-201, a CAR-T cell therapy candidate in early clinical development, is the first step in transferring Nexcella’s existing manufacturing process to the United States.

Sandoz’s marketing authorization applications for a proposed biosimilar to denosumab are supported by a comprehensive analytical and clinical data package.